PHGE Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

BiomX Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerPHGE

Market Cap10.8M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

BiomX Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for BX004 in Chronic Pseudomonas Aeruginosa Infection | Cystic Fibrosis (CF) (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
BX004-A	Chronic Pseudomonas Aeruginosa Infection \| Cystic Fibrosis	n/a	Phase 1 \| Phase 2	Public pipeline row
BX004	Chronic Pseudomonas Aeruginosa Infection \| Cystic Fibrosis (CF)	n/a	Phase 2	Public pipeline row
BX005-A	Atopic Dermatitis	n/a	Phase 1 \| Phase 2	Public pipeline row
BX002-A	n/a	n/a	Phase 1	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT04737876	Phase 1	COMPLETED	18	2020-12-21
NCT05240300	Phase 1 \| Phase 2	WITHDRAWN	n/a	2023-06
NCT05010577	Phase 1 \| Phase 2	COMPLETED	43	2024-03-10
NCT06998043	Phase 2	RECRUITING	63	2026-03

Scientific Context

literature_publication | Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis.
literature_publication | Guidelines of care for the management of atopic dermatitis in pediatric patients.
literature_publication | Clearance of hypermutator XDR Pseudomonas osteomyelitis and hardware infection with adjunctive bacteriophage therapy.
literature_publication | Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.
literature_publication | Focused update: Guidelines of care for the management of atopic dermatitis in adults.

Want the full PHGE research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.